Zach Taiji's Wiki

Company Mentions:
- LEO Pharma picks up momentum as the company’s growth plan progresses. (Citeline)
tralokinumab (ADBRY):
- A user on Reddit posts a comprehensive guide to Eczema, mentioning the importance of asking doctors about newer treatments like ADBRY and EBGLYSS.
- In another Reddit thread, users discuss their experiences transitioning to ADBRY after Dupixent proved ineffective. The outcomes are varied—some report significant improvements with ADBRY, while others experienced only temporary relief and eventually switched to RINVOQ for better results.
delgocitinib (Anzupgo):
- Anzupgo is approved by the by the Medicines and Healthcare Products Regulatory Agency (MHRA) in the UK to treat CHE. (The Pharma Letter, PMLive, Yahoo! Finance, Press release)
- A recent poster presented at the 2024 EADV Congress analyzes a phase 2a study of delgocitinib—finding that it reduces inflammation and restores the skin barrier in CHE as a topical Pan-JAK Inhibitor. (Dermatology Times)

A new study finds that the prevalence of Meniere disease is higher in people with AD—with primary risk factors being older age, female sex, and allergic comorbidities. (HealthDay)
Research from National Jewish Health finds that dupilumab improves the signs and symptoms of AD in young children with co-existing conditions, including asthma, allergic rhinitis, or food allergies. (News Medical, Medical Xpress)
A meta-analysis finds upadacitinib has the highest efficacy in treating AD patients with pruritis, compared to other treatments including DUPIXENT, ADBRY, and EBGLYSS. (Dermatology Times)
An analysis of the Measure Up 1, Measure Up 2, and AD Up trials of upadacitinib finds the treatment effective in treating adolescents with AD through 76 weeks. (Contemporary Pediatrics)
Regeneron takes Sanofi to court, claiming that Sanofi broke a collaboration deal by refusing to reveal side deals for marketing DUPIXENT. (Westfair)
Minghui Pharmaceutical’s phase 3 trial of tofacitinib etocomil (MH004) suggests the treatment is effective in treating patients with AD when applied twice daily. (HCP Live, Clinical Trials Arena)

Dr. Reddy’s Laboratories

Company Mentions:
- Dr. Reddy’s is named winner in the AI Pioneer category at the LinkedIn Talent Awards. (X)
denosumab:
- A new study finds that denosumab was a safe and effective therapy for improving bmd in osteoporotic older men and women with multiple comorbidities in LTC. (X)
- Celltrion presents additional data from its phase III randomized controlled trial to further support the biosimilarity for CT-41 (biosimilar candidate of denosumab). (Press release)
- Denosumab is linked to a higher risk of severe hypocalcemia in older female dialysis-dependent patients. (JAMA)

omadacycline (NUZYRA):
- Paratek files two Patent Term Extension Requests with the U.S. Patent and Trademark Office for NUZYRA. (Press release)
- NUZYRA is renewed for its IV formulation for the treatment of adults with CABP and ABSSSI. (BioSpace)